top bottom line miss lower pt
gilead report revenu vs consensu
sequenti revenu miss flow bottom line non-
gaap ep vs consensu driven larg lower
expect hiv/hbv revenu sequenti gilead end
period cash reiter revenu guidanc
model revis lower revenu estim lower
end guidanc well revenu
non-gaap ep lower
net result pt reduc
hcv increas competit declin patient start led lower sale
price stabil sale still expect stabil mid-year
hiv revenu saw sequenti declin due impact season
inventori decreas gener viread eu taf-bas regimen
see y/i increas biktarvi launch underway approv
sale expect rapidli grow biktarvi overtak
genvoya taf-bas regimen
bright spot car-t still long-term cell therapi play yescarta
revenu beat consensu cancer center on-line
approv expect eu
nash come selonsertib two fulli enrol trial expect
read-out data expect studi
combin studi
conclus lower expect revenu prompt us reduc
estim lower pt
focu reach stabil hcv drive growth hiv biktarvi
gain traction gilead multipl catalyst well
cash could use expand pipelin
hiv biktarvi approv us februari approv eu
expect
nash selonsertib data
data combin studi selonsertib and/or and/or
inflammatory/respiratori filgotinib data psoriat arthriti data
ra finch finch finch data
cutan lupu erythematosu sjogren syndrom
hematology/oncolog yescarta eu approv follow data
look long-term cr rate maintain bcma
trial updat data readout
cell therapi long-term play gilead report expectedli small yescarta
revenu car-t new paradigm take time work
manufactur reimburs us gilead cancer center certifi
prescrib yescarta expect reach popul geograph
gilead posit gener global late stage b-
cell cancer outyear moreov acquir kite gilead first mover
advantag oncolog paradigm shift toward integr cell therapi
treatment regimen begin
exhibit guidanc reiter
exhibit gilead market share hiv
exhibit gilead share treatment naiv
exhibit taf-bas regimen continu overtak tdf
exhibit biktarvi launch follow trend taf-bas uptak us
exhibit genvoya remain prescrib hiv regimen us among new patient
exhibit hcv revenu continu declin amidst increas competit
exhibit target multipl pathway nash
exhibit on-going combin studi advanc nash
exhibit phase data rheumatoid arthriti expect filgotinib
exhibit upcom mileston franchis
thousand except per share data
contract revenu
cog associ car-t
royalti merck us sale harvoni sovaldi
interest incom net
net loss attribut non control interest
net incom attribut gilead
basic ep attribut gilead sharehold
gaap dilut ep attribut gilead sharehold
compani report maxim group estim
